In Segment C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until eventually illness progression or even the members are not able to tolerate the study drugs. - Participant consumed grapefruit or grapefruit products and solutions within 3 https://abbv-744safetyandsideeffe12457.mybuzzblog.com/11600342/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies